Fig. 3From: Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapyChanges of hormone levels during therapy in males regarding therapy outcome. Male therapy responders showed a, barely missed significant, rise in FSH concentrations, paralleled by a non-significant but noticeable drop of testosterone levels. SD/PD (n = 11), CR/PR (n = 7)Back to article page